G01N2650/00

METHODS OF DETERMINING RELATIVE POTENCY OF GLATIRAMER ACETATE AND USE THEREOF IN PREPARING A BATCH OF GLATIRAMER ACETATE AS ACCEPTABLE FOR PHARMACEUTICAL USE
20190025285 · 2019-01-24 ·

A method of determining relative potency of glatiramer acetate (GA) is provided. Accordingly there is provided a method comprising: immunizing a mammal with Poly-YAK copolymer (pYAK); preparing a primary culture of T-cells from the immunized mammal; stimulating samples of the primary culture of T-cells with a reference standard batch of GA or a batch of GA; determining a stimulation parameter of the cells in each sample following a predetermined incubation time; and comparing the stimulation parameter in the cells so as to determine the relative potency of the batch of GA. Also provided are methods of preparing a batch of GA as acceptable for pharmaceutical use and treating multiple sclerosis (MS) in a subject.

ASSAY FOR ANTI-POLYVINYL ALCOHOL ANTIBODIES

An assay method for detecting antipolyvinyl alcohol (anti-PVAL) antibodies in test samples, such as serum, is described. The method comprises combining a sample to be tested for an anti-PVAL antibody with polyvinyl alcohol (PVAL) to form a binary complex of the PVAL with an anti-PVAL antibody in the sample, followed by reacting an indicator reagent with the binary complex to form a labeled ternary complex, and then detecting the presence or absence of the ternary complex in the sample. Kits for performing the test are also described.

CATIONIC POLYMER SYSTEMS FOR SELECTIVE BACTERIAL CAPTURE

A device and methods of use thereof for isolating one or more microorganisms from a biological sample, the device comprising a polymeric surface having one or more cationic polymers covalently grafted thereto, wherein the one or more cationic polymers have a selective affinity for the one or more microorganisms.

PEPTIDE COMPOSITION AND USES THEREOF
20250368693 · 2025-12-04 ·

Subject of the invention is a composition comprising at least one fragment of the peptide ESAT-6 and at least one fragment of the peptide CFP-10. Preferably, the fragments comprise at least two sets of peptides, a first set comprising at least one peptide of from about 7 to 14 amino acid residues in length and a second set comprising at least one peptide of from 16 amino acid residues or greater. The invention also relates to diagnostic methods using the composition.